ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2026
Voice outcomes after office-based hyaluronic acid injection for vocal fold immobility: a prospective single-center study.
Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess the short-term voice quality in unilateral vocal fold paralysis (UVFP) patients after office-based hyaluronic acid injection laryngoplasty (OBIL) using the European Laryngeal Society (ELS) multidimensional voice quality assessment.
methodsPatients with UVFP that underwent OBIL were prospectively recruited from November 2022 to November 2024, at a tertiary university medical center (laryngology unit). Voice handicap index (VHI), GRBAS perceptual evaluation, maximum phonation time (MPT), and acoustic parameters were evaluated seven days and one month post-OBIL. Videolaryngostroboscopy was evaluated to assess the glottic closure (complete or incomplete) using the ELS recommendations.
resultsThirty-two patients with UVFP were included. The amount of injectable ranged from 0.2 mL to 0.8 mL. Improvement in glottal closure was observed in 22/32 (75%) patients at Day-7 and 21/32 (68.8%) at one month post-OBIL. VHI significantly decreased after injection (p = 0.02). Other vocal outcomes (f0, percent jitter, percent shimmer, harmonic to noise ratio) revealed non-significant improvements (p > 0.05). MPT did not change (p = 0.37). Perceptual outcomes decreased non-significantly following OBIL, with 'breathiness' improving the most (p > 0.05).
conclusionOBIL improves voice quality in patients with UVFP. All voice quality outcomes show early improvement at Day-7 and continue to improve at Month-1 after injection. VHI emerged as the most sensitive tool for detecting voice changes.
Indexed as
Identifiers
41353483What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.